Key Highlights

  • Advanced Biomed (NASDAQ:ADVB) was trading down 11.18% at USD 2.94 in pre-market on Friday, November 13, 2026, which implies a prior close of about USD 3.31 (calculated from the screener move).
  • The company priced its initial public offering at USD 4.00 a share in March 2025, selling 1.64 million shares and raising USD 6.56 million, according to published reports.
  • Nasdaq sent a minimum bid price notice on July 18, 2025 after 32 consecutive Business days below USD 1, with a compliance deadline of January 14, 2026.
  • Trailing net loss was USD 3.37 million, or USD 0.16 a share, as of the March 31, 2025 report, and the company reported no revenue.

A Pre-Market Dip With No Announcement Behind It

No company announcement dated November 11 to November 13, 2026 explaining the move was found. Advanced Biomed (NASDAQ:ADVB) is an Investment Holding Company that researches and develops microfluidic biochip technology for precision oncology detection and treatment in Taiwan. Its devices include sample preparation, rare cell detection and circulating tumor cell capture tools. The pre-market change is the figure of record for pre-market only, and the screener's prior close can be unreliable for recent listings. A drop of 11.18% in a micro cap is not by itself news. Where no catalyst is visible, the recent filings and fundamentals matter more, and those are covered below with their dates so that stale figures are not mistaken for current ones.

IPO at USD 4.00, a Slide Below USD 1 and a Price Puzzle

The company went public in March 2025, pricing 1.64 million shares at USD 4.00 for gross proceeds of USD 6.56 million. By May 28, 2025 the stock was at about USD 1.16, down roughly 68% since the IPO, with a 52-week range of USD 0.86 to USD 4.10 at that time. Nasdaq then warned on July 18, 2025 that the bid price had stayed under USD 1 for 32 consecutive business days. Yet Advanced Biomed (NASDAQ:ADVB) now quotes USD 2.94. How it got back above USD 1, for example through a reverse split or a rally, was not found, so the share price history is unverified.

Pre-Revenue Fundamentals and the Risks in a Thin Stock

The last figures found are dated: trailing twelve-month Revenue of zero, a net loss of USD 3.37 million and a Market Value of about USD 26.0 million as of May 2025. No newer quarterly results, cash balance or share count were retrieved, so current valuation is not given. The average weekly price swing was reported at 20.6%, which shows how volatile the stock is. A small number of trades can move the price, spreads can be wide and quoted moves can reverse. Dilution from future financing, listing compliance and the lack of product revenue are the main risks, and an IPO of only USD 6.56 million leaves limited funds for a biochip developer. The next markers are filings with updated financials and any Nasdaq correspondence.

Where Things Stand

The 11.18% pre-market dip has no company-specific explanation in the news found for November 11 to November 13, 2026. Advanced Biomed (NASDAQ:ADVB) is a pre-revenue Taiwan-linked biochip developer with an IPO at USD 4.00, a 2025 bid-price notice and a volatile trading record, and current financials were not located. Treat the move as a swing in a thin stock until the company publishes updated results or other news. The next markers are an updated financial report, any financing announcement and any further Nasdaq letter.